Form 4: Lexeo Therapeutics Director Reinaldo Diaz Granted 25,000 Stock Options

Lexeo Therapeutics, Inc. Director Reinaldo M. Diaz was granted 25,000 stock options with an exercise price of $4.18, aligning his interests with shareholder value.

Summary

• Reinaldo M. Diaz, a Director of Lexeo Therapeutics, Inc. (LXEO), was granted 25,000 stock options.
• The options have an exercise price of $4.18 per share.
• The grant date for these options was June 26, 2025.
• The options are scheduled to expire on June 25, 2035.
• 100% of the shares underlying the option will vest and become exercisable on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, contingent on Mr. Diaz's continuous service.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of stock options to a director is a standard practice that aligns the director's interests with shareholders, indicating a commitment to long-term value creation. No negative information is present.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $4.18 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• The vesting of the options is subject to the reporting person's continuous service, meaning the options could be forfeited if service ceases before vesting.
• The value of the options is dependent on the future market price of Lexeo Therapeutics, Inc. common stock exceeding the exercise price of $4.18.

Future Outlook

The options are forward-looking, with vesting contingent on continued service and future stock performance. The expiration date of June 25, 2035, indicates a long-term incentive.

Industry Context

Equity grants, particularly stock options, are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• NA

Related Party Transactions

• This filing details an equity grant from Lexeo Therapeutics, Inc. to Reinaldo M. Diaz, a director, which is a standard related-party transaction for compensation purposes.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with shareholder value, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Continued service of Reinaldo M. Diaz to meet vesting conditions.
• Potential exercise of options by Reinaldo M. Diaz after vesting, if the stock price is favorable.

Key Dates

Keywords

Lexeo Therapeutics, LXEO, Form 4, Stock Option, Director, Insider Transaction, Equity Grant, Reinaldo Diaz, Beneficial Ownership